Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet | Fortune0

• bond-market, Business, Business / Artificial Intelligence, Business / Big Tech, Business / Companies, Business / Computers and Software, Business / Markets, Business / Social Media, business-idea, business-insider-today, business-strategy, CoECI News, E! Insider, Energy & Environment Newsletter, Finance, Gaming News Roundup, Gear / Gear News and Events, Global, Global Precipitation, global warming, globalstar, HEALTH, Home, House, insider-picks, insider-picks-guides, insider-reviews, insider-reviews-2021, insider-today, job-market, LIFESTYLE, Markets, Markets & Festivals, News, newsletter, Newsletters, Nexstar Media Wire News, People News, Personal Finance, personal-finance, Photovogue / Editorial / News, Politics / Politics News, Property / News, Reviews, reviews-rit-ads, Security / Security News, shop, Shop Beauty
• August 27, 2026

The Food and Drug Administration on Wednesday approved Rasonque, a once-daily pill developed by Revolution Medicines to block several forms of the RAS protein — the mutation that drives tumor growth in most pancreatic cancers, and in roughly a quarter of all human cancers overall. For investors like Dr. Danish Nagda, an early shareholder in